Stonepine Capital Management’s Adicet Bio ACET Stock Holding History

Stonepine Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.51M	Buy	221,955 +1,944	+0.9%	+$14.6K	0.61%	28
2025 Q4	$1.85M	Buy	+220,011	New	+$2.43M	1.35%	24
2025 Q2	–	Sell	-31,767	Closed	-$204K	–	60
2025 Q1	$204K	Sell	31,767 -11,983	-27%	-$171K	0.2%	47
2024 Q4	$673K	Buy	43,750 +5,660	+15%	+$107K	0.54%	36
2024 Q3	$878K	Hold	38,090	–	–	0.55%	27
2024 Q2	$737K	Buy	38,090 +29,243	+331%	+$784K	0.67%	17
2024 Q1	$333K	Buy	+8,847	New	+$366K	0.26%	17
2020 Q1	–	Sell	-730	Closed	-$122K	–	28
2019 Q4	$122K	Buy	+730	New	+$370K	0.09%	22

Other funds holding ACET

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Stonepine Capital Management's ACET Position: Q1 2026 in Review

Stonepine Capital Management increased its Adicet Bio (ACET) stake by 0.88% in Q1 2026, buying an estimated $14.6K and bringing the position to 221,955 shares worth $1.51M. The position accounts for 0.61% of the portfolio, ranked #28.

Stonepine Capital Management first reported a position in ACET in Q4 2019 and has held it in 8 quarters since. The position peaked at $1.85M in Q4 2025. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

Stonepine Capital Management held 221,955 shares of Adicet Bio worth $1.51M as of Q1 2026.
Stonepine Capital Management bought 1,944 Adicet Bio shares in Q1 2026, an estimated $14.6K.
Adicet Bio made up 0.61% of Stonepine Capital Management's portfolio in Q1 2026, its #28 holding.
Stonepine Capital Management first reported a position in Adicet Bio in Q4 2019 and has held it in 8 quarters since.
Stonepine Capital Management's Adicet Bio position peaked at $1.85M in Q4 2025.
49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Stonepine Capital Management's 13F filing for Q1 2026, filed 14 May 2026.